Biotechnology

Faron Pharmaceuticals Ltd: Holding(S) In Company

April 20, 2026 3:20 AM

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Faron Pharmaceuticals OY 1b. Please indicate if the issuer is a...

Read more

New Data from Investigator‑Initiated Study Evaluating Alligator Bioscience’s Mitazalimab to Be Presented at AACR Annual Meeting 2026

April 20, 2026 3:05 AM

Alligator Bioscience (STO:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today announced that new data from a Phase 1 investigator‑initiated trial evaluating intratumoral mitazalimab administered in conjunction with irreversible electroporation (IRE) in locally advanced pancreatic ductal adenocarcinoma (PDAC) will be presented at the American Association for Cancer Research (AACR) Annual...

Read more

Faron Pharmaceuticals LTD: Holding(s) in Company

April 16, 2026 11:15 AM

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Faron Pharmaceuticals Ltd 1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if...

Read more

Regentis Implements Strategy for Commercial Deployment of GelrinC(R) in Europe Through Collaboration with Humanitas Hospital and Leading Cartilage Repair Expert Prof. Elizaveta Kon

April 16, 2026 8:30 AM

Regentis Biomaterials Ltd. ("Regentis" or the "Company") (NYSE American:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, today announced a collaboration with Humanitas Research Hospital in Milan, Italy, one of Europe's leading academic medical centers in orthopedics and sports medicine. This collaboration is currently in the process of being formalized, is expected to support the Company's expanding clinical...

Read more

Microbix Presenting at the 2026 Bloom Burton Conference

April 16, 2026 7:00 AM

Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces it will be attending and presenting at the 2026 Bloom Burton & Co. Healthcare Investor Conference (the "Conference") taking place at the Metro Toronto Convention Centre, North Building, on April 21 and 22, 2026. The Conference provides Microbix the opportunity to build connections with Canadian, U.S., and international...

Read more

American Microbiologist Behind Global Water Safety Breakthrough Wins 2026 Lee Kuan Yew Water Prize

April 16, 2026 2:57 AM

Professor Joan Bray Rose has been awarded the Lee Kuan Yew Water Prize 2026 for her work as a key pioneer in the development and global adoption of Quantitative Microbial Risk Assessment (QMRA), a science-based approach to safeguard the quality of drinking water, as well as water reuse systems. Her work has transformed the science of microbial risk management and guided policies that protect public health and ensure safe water for communities...

Read more

Theis Kipling to Assume Role as CEO of Biovica on May 1, 2026

April 16, 2026 2:20 AM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica today announces that Theis Kipling will assume the role as Chief Executive Officer on May 1, 2026, earlier than previously communicated. In connection with this transition, Anders Rylander will step down as CEO and remain a member of the Board of Directors. As previously announced, Biovica's Board of Directors has appointed Theis Kipling as the company's new CEO. The earlier...

Read more

Faron Announces Collaboration with Parexel to Support Phase IIb BEXERA Trial in Treatment-Naïve HR-MDS

April 16, 2026 2:20 AM

Faron Pharmaceuticals Ltd. ("Faron") (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company focused on creating innovative immunotherapies, today announces that it has entered into an agreement with Parexel International (IRL) Limited, a leading global clinical research organization (CRO), to support the upcoming randomized Phase IIb BEXERA trial in treatment-naïve patients with higher-risk myelodysplastic syndromes (HR-MDS)....

Read more

NatureCell America Achieves FDA IND Approval for Adult Autism Stem Cell Therapy 'AstroStem-AU'

April 15, 2026 8:00 AM

NatureCell Co., Ltd., a biotechnology company focused on adult stem cell therapies led by Chairman Jeong-chan Ra, announced that its U.S. subsidiary, NatureCell America, has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration for AstroStem-AU, an autologous adipose-derived mesenchymal stem cell therapy for adults with Autism Spectrum Disorder (ASD). This IND approval marks the company's formal entry into...

Read more

Microbix Exhibiting & Presenting at ESCMID Global 2026

April 15, 2026 7:00 AM

Microbix Biosystems Inc. (TSX: MBX)(OTCQX:MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it will be exhibiting at ESCMID Global 2026 and presenting results of a novel quality assessment product ("QAP™") to enable full-process quality management of molecular assays to detect an RNA-based virus (e.g., "RT-PCR" tests). ESCMID Global is the Congress of the European Society of Clinical Microbiology and...

Read more

MindMaze Therapeutics Publishes 2025 Annual Report and Corporate Update

April 15, 2026 1:25 AM

MindMaze Therapeutics Holding SA (SIX:MMTX) (MindMaze Therapeutics, or the Company), a global leader in brain technology and precision neurotherapeutics, today announced the publication of its 2025 Annual Report and provided a corporate update highlighting progress toward scalable commercial deployment of its neurotherapeutics platform. "We exist to solve a fundamental problem in neurological care, where the gap between what clinical evidence...

Read more

IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data Readout

April 14, 2026 8:30 AM

IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") today announced that it has approximately 80% patient enrollment in its Phase 2 CALMA clinical trial evaluating IGC-AD1 for agitation associated with Alzheimer's disease. This milestone represents a significant step in advancing the program toward enrollment completion, expected in mid-2026, and positions the Company to progress toward database lock and topline results. Enrollment...

Read more

Lobe Sciences Ltd. Announces Non-Brokered Private Placement

April 10, 2026 8:00 PM

Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE) is pleased to announce a non-brokered private placement offering of 14,615,384 common shares in the capital of the Company ("Common Shares") at a price of $0.065 per Common Share, for aggregate gross proceeds of approximately $950,000 (the "Private Placement"). The Company intends to use the net proceeds of the Private Placement to fund working capital and...

Read more

Notice of Faron Pharmaceuticals LTD's Annual General Meeting

April 10, 2026 9:47 AM

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Shareholders of Faron Pharmaceuticals Ltd (the "Company") are notified of the Annual General Meeting (the "AGM") to be held on 4 May 2026 at 10:00 a.m. EEST (Finnish time) at Putous auditorium at Vierailukeskus JOKI, 2. floor, Lemminkäisenkatu 12 B, FI-20520 Turku, Finland. The registration of attendees and the distribution of voting slips will commence at the meeting venue at 9:30 a.m. EEST (Finnish...

Read more

eXoZymes CCO, Damien Perriman, Outlines NCTx Strategy and the Commercial Path for Cell-Free Biomanufacturing on Grow Everything Podcast

April 10, 2026 9:10 AM

Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transforms abundant feedstock into valuable nutraceuticals and novel medicines - announced that Chief Commercial Officer, Damien Perriman was featured on the latest episode of the industry leading Grow Everything podcast to discuss the company's first spinout, NCTx, and how eXoZymes is building a repeatable commercialization model for high-value natural...

Read more

Alligator Bioscience Provides an Update on Mitazalimab

April 10, 2026 8:30 AM

Alligator Bioscience (STO:ATORX)(Nasdaq Stockholm:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today provided a brief update regarding mitazalimab. In parallel with ongoing partnering activities, Alligator is exploring alternative opportunities for phase 3 development of mitazalimab in first line metastatic pancreatic cancer. As part of these efforts, Alligator has signed a...

Read more

Frontier Bio Wins 'Best Paper' at 50th Annual VESS Meeting for Single-Surgery Regenerative Vascular Graft

April 9, 2026 2:00 PM

Immortal Dragons, the $40 million purpose-driven longevity fund, announced that its portfolio company Frontier Bio has received the Best Paper Award at the 50th Annual Meeting of the Vascular and Endovascular Surgery Society (VESS), one of the three premier national vascular surgery societies, for its novel tissue-engineered vascular graft. Taking place during a period of record-breaking abstract submissions, the 2026 meeting drew broad...

Read more

OSR Holdings Eliminates $2.02 Million Warrant Overhang with Premium-Priced Convertible Note

April 9, 2026 9:15 AM

OSR Holdings, Inc. (NASDAQ:OSRH) ("OSR Holdings" or the "Company") today announced a strategic transaction for capital structure optimization with White Lion GBM Innovation Fund ("White Lion"), centered on the retirement of approximately $2.02 million of warrant overhang. Elimination of $2.02 Million Warrant Overhang As part of the transaction, OSR Holdings has retired approximately $2.02 million of outstanding warrants by consolidating them...

Read more

Imagene AI Announces Collaboration with Daiichi Sankyo to Advance Multimodal Biomarker Discovery in Oncology

April 9, 2026 8:00 AM

Imagene AI, a pioneer in multimodal AI for precision oncology, today announced a collaboration with Daiichi Sankyo (TSE:4568) to advance biomarker discovery and response prediction in oncology drug development. Through this collaboration, Daiichi Sankyo will leverage Imagene AI's OI Suite, a multimodal platform powered by the CanvOI foundation model, to generate biologically grounded insights from Hematoxylin and Eosin (H&E) and...

Read more

Egetis Appoints Tiago Nunes as Chief Medical Officer

April 9, 2026 1:15 AM

Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (STO:EGTX), today announced the appointment of Tiago Nunes, MD, PhD, as Chief Medical Officer (CMO), effective May 1, 2026. Tiago Nunes is an experienced clinical development leader, with significant expertise advancing rare disease therapeutics through regulatory approval and launch, having most recently served as Senior Vice President, Clinical Development at Mirum Pharmaceuticals...

Read more